IOMET PHARMA LTD.

SC376550
Active United Kingdom

Research and experimental development on biotechnology

0 employees website.com
Lifestyle and entertainment Research and experimental development on biotechnology
I

IOMET PHARMA LTD.

SC376550

Research and experimental development on biotechnology

Founded 9 Apr 2010 Active United Kingdom 0 employees website.com
Lifestyle and entertainment Research and experimental development on biotechnology

Previous Company Names

TPP GLOBAL DEVELOPMENT LIMITED 15 Apr 2010 — 19 Aug 2014
CAMVO 195 LIMITED 9 Apr 2010 — 15 Apr 2010
Accounts Submitted 10 Sept 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 15 Apr 2026 Next due 23 Apr 2027 10 months remaining
Net assets £8M £356K 2023 year on year
Total assets £8M £381K 2023 year on year
Total Liabilities £161K £26K 2023 year on year
Charges None No charges registered

Contact & Details

Contact

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for IOMET PHARMA LTD. (SC376550), an active lifestyle and entertainment company based in United Kingdom. Incorporated 9 Apr 2010. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2014–2023)

Cash in Bank

£8.07M

Increased by £365.78k (+5%)

Net Assets

£7.94M

Increased by £355.82k (+5%)

Total Liabilities

£161.31k

Increased by £25.62k (+19%)

Turnover

N/A

Employees

N/A

Debt Ratio

2%

Financial History

Revenue, profit, EBITDA and key financial figures

2023
31 Dec Year End
2022
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (2)

Investor NameInvestor SinceParticipating Rounds
Investor 1Jul 2010Series A
Investor 2Jan 2016Acquisition

Share Capital

Share Capital

Share allotments and capital structure

6 Allotments 2,862 Shares £70.07m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
6 Feb 20201,000£10.00m£10k
20 Dec 20181,000£22.50m£23k
20 Dec 20171£35.00m£35.00m
31 Oct 20171£1.00m£1.00m
21 Jun 20161£1.50m£1.50m

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Merck Sharp & Dohme Corp.
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Merck & Co., Inc.

United States Of America

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,voting Rights 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

IOMET PHARMA LTD. Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
15 Apr 2026OfficersChange to director Ebru Can Temucin on 16 Aug 2018
15 Apr 2026Confirmation StatementConfirmation statement made on 9 Apr 2026 with no updates
10 Sept 2025AccountsAnnual accounts made up to 31 Dec 2024
15 Apr 2025Confirmation StatementConfirmation statement made on 9 Apr 2025 with no updates
18 Sept 2024AccountsAnnual accounts made up to 31 Dec 2023
15 Apr 2026 Officers

Change to director Ebru Can Temucin on 16 Aug 2018

15 Apr 2026 Confirmation Statement

Confirmation statement made on 9 Apr 2026 with no updates

10 Sept 2025 Accounts

Annual accounts made up to 31 Dec 2024

15 Apr 2025 Confirmation Statement

Confirmation statement made on 9 Apr 2025 with no updates

18 Sept 2024 Accounts

Annual accounts made up to 31 Dec 2023

Recent Activity

Latest Activity

Change to director Ebru Can Temucin on 16 Aug 2018

2 months ago on 15 Apr 2026

Confirmation statement made on 9 Apr 2026 with no updates

2 months ago on 15 Apr 2026

Annual accounts made up to 31 Dec 2024

9 months ago on 10 Sept 2025

Confirmation statement made on 9 Apr 2025 with no updates

1 years ago on 15 Apr 2025

Annual accounts made up to 31 Dec 2023

1 years ago on 18 Sept 2024